Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer

E. H. Tan1* J. Rolski2 T. Grodzki3 C. P. Schneider4 U. Gatzemeier5 P. Zatloukal6 E. Aitini7 G. Carteni8 H. Riska9 Y. H. Tsai10 and R. Abratt11

首页> 外文期刊>Annals of Oncology >Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer

【24h】

Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer

机译：全球肺肿瘤科试验3（GLOB3）：口服和静脉注射交替进行的跨国多国III期研究的最终结果。长春瑞滨联合顺铂与多西他赛联合顺铂一线治疗晚期非小细胞肺癌

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: The study compared the efficacy of a first-line treatment with day 1 i.v. vinorelbine (NVBiv) and day 8 oral vinorelbine (NVBo) versus docetaxel (DCT) in a cisplatin-based combination in advanced non-small-cell lung cancer, in terms of time to treatment failure (TTF), overall response, progression-free survival (PFS), overall survival (OS), tolerance and quality of life (QoL).

机译：背景：该研究比较了静脉注射第一天和第一天的疗效。长春瑞滨（NVBiv）和第8天口服长春瑞滨（NVBo）与多西他赛（DCT）在以顺铂为基础的联合治疗晚期非小细胞肺癌中的治疗失败时间（TTF），总体反应，无进展生存率（PFS），总体生存率（OS），耐受性和生活质量（QoL）。

著录项

来源
《Annals of Oncology》 |2009年第7期|p.1249-1256|共8页
作者
E. H. Tan1* J. Rolski2 T. Grodzki3 C. P. Schneider4 U. Gatzemeier5 P. Zatloukal6 E. Aitini7 G. Carteni8 H. Riska9 Y. H. Tsai10 and R. Abratt11;
展开▼
作者单位

1Department of Medical Oncology, National Cancer Centre, Singapore 2Department of Medical Oncology, Centre of Oncology, Maria Sklodowska-Curie, Memorial Institute, Crakow 3Department of Chemotherapy, The Regional Hospital for Lung Diseases, Szczecin-Zdunowo, Poland 4Central Hospital Bad Berka, Bad Berka 5Department of Pneumo-Oncology, Hospital Grosshansdorf, Centre of Pneumology and Thoracic Surgery, Grosshansdorf, Germany 63rd Faculty of Medicine, Charles University, Postgraduate Medical School and Faculty Hospital Bulovka, Prague, Czech Republic 7Oncology and Haematology Operative Unit, Carlo Poma Hospital, Mantova 8Medical Oncology Operative Unit, Antonio Cardarelli Hospital, Naples, Italy 9Helsinki University Central Hospital, Meilahden Sairaala Haartmaninkaku, Helsinki, Finland
展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. [J] . Tan EH, Rolski J, Grodzki T Annals of oncology: official journal of the European Society for Medical Oncology . 2009,第7期

机译：全球肺肿瘤科试验3（GLOB3）：口服和静脉注射交替进行的跨国多国III期研究的最终结果。长春瑞滨联合顺铂与多西他赛联合顺铂作为晚期非小细胞肺癌的一线治疗。
2. 6501 ORAL Global Lung Oncology Branch trial 3 (GLOB 3): Quality of Life (QoL) results of a randomised multinational Phase III trial of oral and i.v. vinorelbine (NVB) plus cisplatin (CDDP) versus docetaxel (DTX) plus CDDP as first-line treatment for advanced non-small cell lung cancer (NSCLC) [J] . J.Rolski, T.Grodzki, C.P.Schneider, European Journal of Cancer Supplements . 2007,第4期

机译：6501 ORAL全球肺肿瘤科试验3（GLOB 3）：一项针对口服和静脉注射的跨国多国III期随机试验的生活质量（QoL）结果。长春瑞滨（NVB）加顺铂（CDDP）与多西他赛（DTX）加CDDP作为晚期非小细胞肺癌（NSCLC）的一线治疗
3. Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study. [J] . Douillard JY, Gervais R, Dabouis G, Annals of oncology: official journal of the European Society for Medical Oncology . 2005,第1期

机译：IV期非小细胞肺癌的连续两线治疗策略：多西他赛-顺铂与长春瑞滨-顺铂，然后在进展时转用单药多西他赛或长春瑞滨：一项II期随机研究的最终结果。
4. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial [O] . K. Kubota, H. Sakai, N. Katakami, -1

机译：TCOG0701 CATS试验在日本晚期非小细胞肺癌患者中口服S-1加顺铂与多西他赛加顺铂进行的随机III期试验：
5. PD4-2-3: Global Lung Oncology Branch trial 3 (Glob 3): final results of a randomised multinational Phase III study of oral and i.v. vinorelbine (NVB) plus cisplatin (CDDP) versus docetaxel (DTX) plus CDDP as first-line treatment for advanced Non-Small Cell Lung Cancer (NSCLC) [O] . Tan Eng-Huat, Grodzki Tomasz, Schneider Claus-Peter, 2007

机译：PD4-2-3：全球肺肿瘤科试验3（Glob 3）：一项针对口服和静脉注射的跨国多国III期随机研究的最终结果长春瑞滨（NVB）加顺铂（CDDP）与多西他赛（DTX）加CDDP作为晚期非小细胞肺癌（NSCLC）的一线治疗

Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer

摘要

著录项

相似文献

相关主题

期刊订阅